# Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

> **NCT00002386** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 55 (—)

## Conditions studied

- HIV Infections
- Hemophilia A

## Interventions

- **DRUG:** Indinavir sulfate
- **DRUG:** Lamivudine
- **DRUG:** Stavudine
- **DRUG:** Zidovudine
- **DRUG:** Zalcitabine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002386
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 55 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002386, "Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00002386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*